Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Marcos Garza-Madrid"'
Autor:
Shoumyo Majumdar, Qiongyu Guo, Xiomara Calderon-Colon, Marcos Garza-Madrid, Oliver D. Schein, Morgana M. Trexler, Priscilla Carbajal, Derek Duan, Jennifer H. Elisseeff
Publikováno v:
Journal of Biomedical Materials Research Part B: Applied Biomaterials. 104:300-307
Collagen vitrigel membranes are transparent biomaterials characterized by a densely organized, fibrillar nanostructure that show promise in the treatment of corneal injury and disease. In this study, the influence of different type I collagen sources
Publikováno v:
Process Biochemistry. 45:1082-1087
In the present research, the potential use of flexible disposable devices, specifically blood bags, for the fractionation of biological products using Aqueous Two-Phase Systems (ATPS) polymer–salt is studied and demonstrated. Purified human serum a
Autor:
Shoumyo, Majumdar, Qiongyu, Guo, Marcos, Garza-Madrid, Xiomara, Calderon-Colon, Derek, Duan, Priscilla, Carbajal, Oliver, Schein, Morgana, Trexler, Jennifer, Elisseeff
Publikováno v:
Journal of biomedical materials research. Part B, Applied biomaterials. 104(2)
Collagen vitrigel membranes are transparent biomaterials characterized by a densely organized, fibrillar nanostructure that show promise in the treatment of corneal injury and disease. In this study, the influence of different type I collagen sources
Autor:
Julio C. Rojas-Martinez, Luis Villela, Irene Anaya, Maria de la Luz Mendizabal, Rosa E. De Leon, José DeDiego, Leonel Ochoa, Jorge Duque, Roberto Hernandez, Guadalupe Gonzalez, Martha Alvarado, Severiano Baltazar, Jose R. Borbolla Escoboza, Eduardo Romero, Teresa Pompa, Jorge L. Juarez, Rosa María Romero Jiménez, Jason A. Penniecook, Enrique Baez, Marcos Garza-Madrid, Monica Tejeda, Maria I. Leon-Castanon, Yara E. Tovar, Carlos Gil-Rondero, Manuel López-Hernández, Elvira Trueba, Cecilia Ramirez-Assad, Jorge Cruz-Rico, Mauricio González-Avante, Dolores Mejia, Gerardo Villarreal
Publikováno v:
Blood. 104:4312-4312
Although there have been extraordinary advances in leukemia therapy, there is still a large subset of cases in which complete remission or prolonged leukemia-free survival cannot be achieved. Some of this variability in results is thought to be relat